COLLABORATING VASCULITIS PATIENT GROUPS
The latest news......
Fasenra not reimbursed in France
French EGPA patients and their doctors received disappointing news recently when the French health authority (HAS) decided not to reimburse Fasenra (benralizumab) for treating EGPA. This decision has created significant concern within the EGPA community, as it limits access to what could be an important alternative treatment option.
EESG Meeting in Paris
On September 18th, 2025, leading EGPA specialists from across Europe gathered in Paris for the 10th meeting of the European EGPA Study Group. The research-focused conference, held at the historic Maison de l’Amérique Latine, brought together doctors and researchers to present and discuss the latest scientific developments in understanding and treating this rare autoimmune condition. A small number of patient representatives also attended this primarily medical meeting.
Reducing prednisone in EGPA
An additional analysis from the MANDARA study shows that steroid-free remission is possible for a subset of patients with EGPA. Biologic therapies such as benralizumab and mepolizumab can support this goal, with benralizumab showing somewhat better outcomes in this specific context.
patients
Find Patient Advocacy Groups (VPAGs)
hospitals
Find vasculitis expertise
projects
Find out about the projects we are working on.